Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Eli Lilly And Co. (LLY)
Lilly's Jaypirca Combo Reduces Risk Of Progression By 45% In Phase 3 CLL Trial
6/14/2026 4:56:48 AM
Eli Lilly Unveils Promising Data On First-in-Class Type II JAK2 Inhibitor For Myelofibrosis
6/13/2026 11:21:52 AM
Lilly Receives FDA Nod For EBGLYSS Eight-Week Subcutaneous Maintenance Dose In Atopic Dermatitis
6/10/2026 1:01:35 AM
Eli Lilly Secures FDA Approval For EBGLYSS In Moderate-to-Severe Atopic Dermatitis
6/10/2026 12:24:20 AM
FDA Approves Lilly's EBGLYSS For 1 Maintenance Dose Every 8 Weeks In Patients With Moderate-to-severe Atopic Dermatitis
6/9/2026 7:51:17 PM
Lilly's Orforglipron Delivers Superior HbA1C Control And Weight Loss In 3 Phase 3 Diabetes Trials
6/9/2026 5:22:44 AM
Lilly's Foundayo Delivers Superior A1C And Weight Loss In Three Pivotal Diabetes Trials
6/8/2026 8:49:24 PM
Lilly's Retatrutide Delivers Landmark Phase 3 Results Across Obesity And Related Conditions
6/8/2026 6:16:35 AM
Lilly's Foundayo Demonstrates Weight Loss Across Menopause Stages
6/7/2026 11:29:19 AM
Lilly’s Foundayo Shows Significant Weight Loss Across Menopause Stages
6/7/2026 11:11:51 AM
Lilly’s Retatrutide Shows Breakthrough Benefits In Obesity And Related Conditions
6/6/2026 9:39:22 PM
Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN
6/5/2026 10:26:20 AM
Ascidian Therapeutics, Eli Lilly Join Hands To Develop Devastating Kidney Disease Therapies
6/3/2026 8:08:00 AM
Ascidian Therapeutics And Eli Lilly Announce RNA Collaboration For Kidney Disease Therapies
6/3/2026 7:54:18 AM
Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Today
6/1/2026 12:21:58 PM
Hanmi Partners With Lilly On Sonefpeglutide Development; Stock Up
6/1/2026 1:26:42 AM
Lilly And Hanmi Pharm Ink Licensing Agreement For Sonefpeglutide
6/1/2026 12:57:46 AM
Hanmi Licenses Sonefpeglutide To Eli Lilly For Development And Commercialization
5/31/2026 11:17:25 PM
Eli Lilly's Retevmo Phase 3 LIBRETTO-432 Cuts Recurrence Risk 83% In RET+ Early-Stage NSCLC
5/31/2026 8:26:50 AM
Eli Lilly’s Retevmo Delivers 83% Risk Reduction In Phase 3 LIBRETTO-432 Trial For RET Fusion-Positive NSCLC
5/31/2026 8:07:09 AM
1
2
3
4
Next
»